Nebivolol Glenmark (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑blocker that acts on the cardiovascular system to lower blood pressure and improve heart function.

• Hypertension: reduces systolic and diastolic blood pressure, helping to control essential hypertension.
• Heart failure with reduced ejection fraction: improves ventricular performance and may reduce hospitalization risk.
• Cardiovascular risk management: contributes to overall risk reduction in patients with elevated blood pressure and associated comorbidities.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which lowers cardiac output. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, further contributing to blood pressure reduction without significant β2‑blockade.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness: often related to blood pressure changes.
• Fatigue or tiredness: may occur during dose titration.
• Bradycardia: slower heart rate, usually asymptomatic.
• Nausea or abdominal discomfort.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia or heart block: may require medical attention.
• Acute bronchospasm: especially in patients with asthma or COPD.
• Allergic reactions: rash, itching, or angioedema.
• Hepatic dysfunction: elevated liver enzymes.
• Hypotension: marked drop in blood pressure leading to syncope.
• Depression or mood changes: rare but reported.

Before initiating Nebivolol, clinicians should evaluate patient history and monitor relevant parameters.

• Cardiovascular assessment: verify baseline heart rate and blood pressure.
• Asthma or COPD: use with caution due to potential bronchospasm.
• Diabetes: monitor blood glucose as symptoms of hypoglycemia may be masked.
• Renal or hepatic impairment: dose adjustment may be required.
• Abrupt discontinuation: taper gradually to avoid rebound hypertension.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; careful review is advised.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels.
• Non‑selective β‑blockers combined with nebivolol: heightened cardiovascular depression.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may enhance hypotensive effect.

• Diuretics: increase risk of orthostatic hypotension.
• Antidiabetic agents: may mask hypoglycemia symptoms, requiring glucose monitoring.